Citigroup’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Citigroup’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-122	Closed	-$221	–	5861
2023 Q2	$221	Buy	122 +69	+130%	+$126	﹤0.01%	5424
2023 Q1	$70	Sell	53 -178	-77%	-$291	﹤0.01%	5308
2022 Q4	$390	Sell	231 -290	-56%	-$367	﹤0.01%	5536
2022 Q3	$1K	Sell	521 -1,261	-71%	-$3.76K	﹤0.01%	5734
2022 Q2	$5K	Sell	1,782 -1,049	-37%	-$6.4K	﹤0.01%	5648
2022 Q1	$20K	Buy	+2,831	New	+$27.8K	﹤0.01%	5162

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citigroup's PRDS Position: Q3 2023 in Review

Citigroup sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 122 shares — an estimated $221 sold.

Citigroup first reported a position in PRDS in Q1 2022 and held it in 6 quarters. The position peaked at $20K in Q1 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Citigroup reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Citigroup sold 122 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $221.
Citigroup first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Citigroup's Pardes Biosciences, Inc. Common Stock position peaked at $20K in Q1 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Citigroup's 13F filing for Q3 2023, filed 9 Nov 2023.